NCT00036296View on ClinicalTrials.gov

Effects of Talampanel on Patients With Advanced Parkinson's Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions
DyskinesiasParkinson DiseaseMovement Disorders
Interventions
DRUG

talampanel

75mg per day divided into 3 doses for 22 days

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT00036296 - Effects of Talampanel on Patients With Advanced Parkinson's Disease | Biotech Hunter | Biotech Hunter